Caroline Wei Shan Hoong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caroline Wei Shan Hoong has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Jad G. Sfeir
Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester , Rochester, MN 55905
3 shared publications Jaime Hui Xian Lin
Division of Endocrinology, Department of Medicine Woodlands Health Campus Singapore Singapore Singapore
3 shared publications- Bart Lyman Clarke
Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester , Rochester, MN 55905
2 shared publications - Ester Yeoh
Diabetes Centre Admiralty Medical Centre Singapore Singapore
2 shared publications Huilin Koh
Division of Endocrinology, Department of Medicine Woodlands Health Campus Singapore Singapore Singapore
2 shared publicationsSay Tat Ooi
Clinical Epidemiology Unit, Khoo Teck Puat Hospital, Singapore, Singapore
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
Establishing guidelines-based multidisciplinary diabetic limb salvage programme: A 100-day review of clinical characteristics and outcomes
Objectives: A newly established hospital in Singapore has introduced a pioneering multidisciplinary diabetic foot programme to provide comprehensive care for patients with diabetic foot ulcers. This study evaluates the early outcomes of a multidisciplinary diabetic limb salvage programme. Over the first 100 days of operation, the diabetic foot programme managed 106 patients. Methods: A descriptive statistical analysis was conducted to evaluate clinical characteristics and outcomes at 100 days of follow-up. Results: The majority of patients were Malay (46.2%) and male (61.3%), with a median age of 63.5 years. Most patients had long-standing diabetes and poor glycaemic control (77.8%), leading to high rates of diabetes-related complications. A total of 18.3% of patients had osteomyelitis, and 11.7% had gangrene. Of the 106 patients, 61.3% required inpatient management, 25.5% underwent revascularisation, and 34.9% had diabetic foot ulcer-related surgeries. According to Wound, Ischaemia and Foot Infection 12-month risk stratification, nearly 30% of patients were at medium to high risk of major lower extremity amputation. Minor lower extremity amputation occurred in 15.1% of patients and 4.7% required major lower extremity amputation. The 30-day mortality rate was 3.8%, and the average length of stay was 15.7 days. The time from admission to revascularisation was 4.4 days, and the time to diabetic foot ulcer-related surgery was 4.2 days. Wound healing was documented in 34.8% of patients at 100 days of follow-up, with a healing time of 63.2 days. Conclusion: Our guidelines based, multidisciplinary diabetic limb salvage programme demonstrated favourable limb salvage outcomes despite high predicted amputation risks. The early outcomes of this programme highlight the effectiveness of early medical optimisation, infection control, revascularisation and active wound care.
- 1 July 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
Open AccessEstablishing guidelines-based multidisciplinary diabetic limb salvage programme: A 100-day review of clinical characteristics and outcomes
Objectives: A newly established hospital in Singapore has introduced a pioneering multidisciplinary diabetic foot programme to provide comprehensive care for patients with diabetic foot ulcers. This study evaluates the early outcomes of a multidisciplinary diabetic limb salvage programme. Over the first 100 days of operation, the diabetic foot programme managed 106 patients. Methods: A descriptive statistical analysis was conducted to evaluate clinical characteristics and outcomes at 100 days of follow-up. Results: The majority of patients were Malay (46.2%) and male (61.3%), with a median age of 63.5 years. Most patients had long-standing diabetes and poor glycaemic control (77.8%), leading to high rates of diabetes-related complications. A total of 18.3% of patients had osteomyelitis, and 11.7% had gangrene. Of the 106 patients, 61.3% required inpatient management, 25.5% underwent revascularisation, and 34.9% had diabetic foot ulcer-related surgeries. According to Wound, Ischaemia and Foot Infection 12-month risk stratification, nearly 30% of patients were at medium to high risk of major lower extremity amputation. Minor lower extremity amputation occurred in 15.1% of patients and 4.7% required major lower extremity amputation. The 30-day mortality rate was 3.8%, and the average length of stay was 15.7 days. The time from admission to revascularisation was 4.4 days, and the time to diabetic foot ulcer-related surgery was 4.2 days. Wound healing was documented in 34.8% of patients at 100 days of follow-up, with a healing time of 63.2 days. Conclusion: Our guidelines based, multidisciplinary diabetic limb salvage programme demonstrated favourable limb salvage outcomes despite high predicted amputation risks. The early outcomes of this programme highlight the effectiveness of early medical optimisation, infection control, revascularisation and active wound care.
- Open Access
- 9 March 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (5) , ziaf040
Gallium-68-DOTATATE PET/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia
Gallium-68-DOTA-Tyr3-Octreotate (Ga-68-DOTATATE) positron emission tomography/computed tomography (PET/CT) has recently been shown to have utility for the localization of phosphaturic mesenchymal tumors (PMT) that cause tumor-induced osteomalacia (TIO), a rare renal phosphate-wasting disorder. The aim of this study was to evaluate the accuracy of Ga-68-DOTATATE PET/CT in localizing PMTs causing TIO and to compare its performance with other functional imaging modalities. Prospective recruitment and retrospective chart review of 30 patients with suspected TIO and evaluation with Ga-68-DOTATATE PET/CT between 2017 and 2023 were conducted at a tertiary medical center. True positive (TP) lesions were defined by histological confirmation of PMT. There were 22 TP lesions identified among 18 patients, with a mean SUVmax of 16.8 (±10.9). Sensitivity, specificity, and accuracy of Ga-68-DOTATATE PET/CT were 85.7%, 77.8%, and 83.3% on patient-based analysis, and 84.6%, 56.3%, and 73.8% on lesion-based analysis. Lesions such as subacute fractures, parathyroid adenomas, thymus uptake, vertebral hemangiomas, bone enchondromas, liver hemangiomas, and avascular necrosis were some of the pitfalls in interpretation. Ga-68-DOTATATE PET/CT led to a significant impact on clinical management in 24 (80%) of patients. The presence of DOTATATE-avid fractures was significantly associated with a localizing scan on univariable (OR 15.0, 95% CI 2.80-110, p = .001) and multivariable analysis (OR 9.45, 95% CI 1.33-98.4, p = .003). Ga-68-DOTATATE PET/CT has good accuracy for the localization of TIO, with superior sensitivity compared to F-18-FDG PET/CT. This significantly impacted clinical treatment decisions. Although DOTATATE-avid fractures may be a source of false positives, they may also indicate a higher probability of a localizing study.
- 9 March 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (5) , ziaf040
Open AccessGallium-68-DOTATATE PET/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia
Gallium-68-DOTA-Tyr3-Octreotate (Ga-68-DOTATATE) positron emission tomography/computed tomography (PET/CT) has recently been shown to have utility for the localization of phosphaturic mesenchymal tumors (PMT) that cause tumor-induced osteomalacia (TIO), a rare renal phosphate-wasting disorder. The aim of this study was to evaluate the accuracy of Ga-68-DOTATATE PET/CT in localizing PMTs causing TIO and to compare its performance with other functional imaging modalities. Prospective recruitment and retrospective chart review of 30 patients with suspected TIO and evaluation with Ga-68-DOTATATE PET/CT between 2017 and 2023 were conducted at a tertiary medical center. True positive (TP) lesions were defined by histological confirmation of PMT. There were 22 TP lesions identified among 18 patients, with a mean SUVmax of 16.8 (±10.9). Sensitivity, specificity, and accuracy of Ga-68-DOTATATE PET/CT were 85.7%, 77.8%, and 83.3% on patient-based analysis, and 84.6%, 56.3%, and 73.8% on lesion-based analysis. Lesions such as subacute fractures, parathyroid adenomas, thymus uptake, vertebral hemangiomas, bone enchondromas, liver hemangiomas, and avascular necrosis were some of the pitfalls in interpretation. Ga-68-DOTATATE PET/CT led to a significant impact on clinical management in 24 (80%) of patients. The presence of DOTATATE-avid fractures was significantly associated with a localizing scan on univariable (OR 15.0, 95% CI 2.80-110, p = .001) and multivariable analysis (OR 9.45, 95% CI 1.33-98.4, p = .003). Ga-68-DOTATATE PET/CT has good accuracy for the localization of TIO, with superior sensitivity compared to F-18-FDG PET/CT. This significantly impacted clinical treatment decisions. Although DOTATATE-avid fractures may be a source of false positives, they may also indicate a higher probability of a localizing study.
- 6 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , 2573-2583
Prognostic Factors for Refractory Outcome in Localizing TIO: Experience in a Tertiary Center
Context: Tumor-induced osteomalacia (TIO), a paraneoplastic disorder characterized by renal phosphate wasting, is cured by surgical removal of the culprit tumor. Despite correct localization, some remain refractory to intervention, resulting in substantial long-term medical complications. Objective: We aim to identify risk factors associated with a refractory outcome. Methods: This is a retrospective cohort of 44 patients with TIO diagnosed from 1998 to 2023 who underwent targeted intervention following successfully localization. Cure was defined as maintenance of normophosphatemia without supplementation for ≥1 month, maintained at last follow-up. Results: Twenty-nine patients achieved cure and 15 had a refractory outcome. On univariate Cox regression, the HR for predicting cure was 3.43 (95% CI 1.45-8.11, P = .005) for patients diagnosed after 2013 (compared to before), and that for a negative surgical tumor margin was 2.56 (95% CI 1.20-5.45, P = .015) compared to positive/unspecified margins. After adjustment for year of diagnosis, tumors originating from soft tissue (HR 2.72 vs bone, 95% CI 1.22-6.09, P = .015) or located outside the spine (HR 0.22 for spine vs nonspine, 95% CI 0.05-0.96, P = .043) had higher chances of cure. Size of tumor, age, gender, or baseline biochemistry including levels of fibroblast growth factor (FGF)23, phosphorus, 1,25-dihydroxyvitamin D, or alkaline phosphatase were not predictive of cure. Postprocedural FGF23 was the best biochemical marker of cure (area under curve 0.899, 95% CI 0.764-1.00, P < .001). Conclusion: Tumors diagnosed within the past decade with clear resection margins had more favorable prognoses. With regards to tumoral factors, baseline biochemistry was uninformative in predicting cure, while bone and/or spine localizations were associated with a refractory outcome.
- 6 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , 2573-2583
Prognostic Factors for Refractory Outcome in Localizing TIO: Experience in a Tertiary Center
Context: Tumor-induced osteomalacia (TIO), a paraneoplastic disorder characterized by renal phosphate wasting, is cured by surgical removal of the culprit tumor. Despite correct localization, some remain refractory to intervention, resulting in substantial long-term medical complications. Objective: We aim to identify risk factors associated with a refractory outcome. Methods: This is a retrospective cohort of 44 patients with TIO diagnosed from 1998 to 2023 who underwent targeted intervention following successfully localization. Cure was defined as maintenance of normophosphatemia without supplementation for ≥1 month, maintained at last follow-up. Results: Twenty-nine patients achieved cure and 15 had a refractory outcome. On univariate Cox regression, the HR for predicting cure was 3.43 (95% CI 1.45-8.11, P = .005) for patients diagnosed after 2013 (compared to before), and that for a negative surgical tumor margin was 2.56 (95% CI 1.20-5.45, P = .015) compared to positive/unspecified margins. After adjustment for year of diagnosis, tumors originating from soft tissue (HR 2.72 vs bone, 95% CI 1.22-6.09, P = .015) or located outside the spine (HR 0.22 for spine vs nonspine, 95% CI 0.05-0.96, P = .043) had higher chances of cure. Size of tumor, age, gender, or baseline biochemistry including levels of fibroblast growth factor (FGF)23, phosphorus, 1,25-dihydroxyvitamin D, or alkaline phosphatase were not predictive of cure. Postprocedural FGF23 was the best biochemical marker of cure (area under curve 0.899, 95% CI 0.764-1.00, P < .001). Conclusion: Tumors diagnosed within the past decade with clear resection margins had more favorable prognoses. With regards to tumoral factors, baseline biochemistry was uninformative in predicting cure, while bone and/or spine localizations were associated with a refractory outcome.
- Open Access
- 31 May 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (7) , ziae074
Natural history and complications of normocalcemic hyperparathyroidism: a retrospective cohort study
Normocalcemic hyperparathyroidism (NHPT) is variably defined, and information regarding complications and natural history are scarce. We aimed to describe the phenotype of NHPT in relation to hypercalcemic hyperparathyroidism (PHPT) and controls, to determine risk of progression, and to develop a predictive model for progression to PHPT. This is a retrospective chart review of 232 patients at a tertiary medical center, comparing 75 controls, 73 patients with NHPT, and 84 with PHPT. NHPT was intermediate in biochemical profile between controls and PHPT with respect to cCa, iPTH, intraindividual coefficient of variant of cCa, phosphorus, and 25(OH)D. NHPT patients had an increased adjusted risk of urolithiasis (OR 5.34, 95%CI, 2.41-12.71, P < .001) and fragility fractures (OR 4.53, 95%CI, 1.63-14.84, P = .006) versus controls, after adjustment for age, sex, and BMI. Fewer NHPT compared with PHPTH patients achieved cure with parathyroidectomy (P = .001). NHPT more often had nonlocalizing imaging or polyglandular disease (P = .005). Parathyroidectomy improved biochemical but not BMD parameters in NHPT. Over a median follow-up of 4.23 (IQR 1.76-5.31) years, NHPT patients managed expectantly experienced no change in iPTH, and progression to PHPT occurred in 9%. An XGBoost model combining 6 factors for progression (mean index 2 iPTH, mean index 2 cCa, 24-h urinary calcium, age, 25(OH)D, and presence of urolithiasis) had an area under the curve 1.00 (95%CI, 1.00-1.00, P < .001) for predicting combined progression. NHPT is a mild variant of PHPT at intermediate risk of urolithiasis and fragility fractures. Cure was less often achieved with parathyroidectomy, which did not improve BMD parameters. Progression was infrequent with conservative management. Because only a minority progressed to PHPT, in addition to lower surgical success rates, we suggest conservative management for the majority of NHPT unless risk factors for progression are identified.
- 31 May 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (7) , ziae074
Open AccessNatural history and complications of normocalcemic hyperparathyroidism: a retrospective cohort study
Normocalcemic hyperparathyroidism (NHPT) is variably defined, and information regarding complications and natural history are scarce. We aimed to describe the phenotype of NHPT in relation to hypercalcemic hyperparathyroidism (PHPT) and controls, to determine risk of progression, and to develop a predictive model for progression to PHPT. This is a retrospective chart review of 232 patients at a tertiary medical center, comparing 75 controls, 73 patients with NHPT, and 84 with PHPT. NHPT was intermediate in biochemical profile between controls and PHPT with respect to cCa, iPTH, intraindividual coefficient of variant of cCa, phosphorus, and 25(OH)D. NHPT patients had an increased adjusted risk of urolithiasis (OR 5.34, 95%CI, 2.41-12.71, P < .001) and fragility fractures (OR 4.53, 95%CI, 1.63-14.84, P = .006) versus controls, after adjustment for age, sex, and BMI. Fewer NHPT compared with PHPTH patients achieved cure with parathyroidectomy (P = .001). NHPT more often had nonlocalizing imaging or polyglandular disease (P = .005). Parathyroidectomy improved biochemical but not BMD parameters in NHPT. Over a median follow-up of 4.23 (IQR 1.76-5.31) years, NHPT patients managed expectantly experienced no change in iPTH, and progression to PHPT occurred in 9%. An XGBoost model combining 6 factors for progression (mean index 2 iPTH, mean index 2 cCa, 24-h urinary calcium, age, 25(OH)D, and presence of urolithiasis) had an area under the curve 1.00 (95%CI, 1.00-1.00, P < .001) for predicting combined progression. NHPT is a mild variant of PHPT at intermediate risk of urolithiasis and fragility fractures. Cure was less often achieved with parathyroidectomy, which did not improve BMD parameters. Progression was infrequent with conservative management. Because only a minority progressed to PHPT, in addition to lower surgical success rates, we suggest conservative management for the majority of NHPT unless risk factors for progression are identified.
- 20 March 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (2) , e397-e411
A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease
Context: Tumor-induced osteomalacia (TIO) is a rare condition with evidence mostly derived from case reports and case series. Objective: We aimed to describe the clinical characteristics of a large cohort of patients diagnosed with TIO, with a focus on patients with nonlocalizing and malignant TIO. Methods: This is a retrospective cohort of patients with TIO in an academic medical center, diagnosed between January 1998 and May 2023. We describe their demographics, biochemistries, tumor features, localization, treatment, and complications. Results: Of 68 patients diagnosed with TIO, 49 (72%) were localizing and 5 (7.4%) were malignant. Of 50 patients who attempted localizing procedures, 29 (58%) achieved cure. Twenty (40%) had persistent disease due to the wrong tumor targeted, or refractory or recurrent tumors, despite up to 6 procedural attempts. There was no difference in demographics, phosphorus, or baseline fibroblast growth factor-23 (FGF23) levels between localizing vs nonlocalizing groups, and malignant vs nonmalignant groups. The lower extremity was the commonest site of localization (37%), with 47% in bone and 53% in soft tissue. Sixty percent of malignant cases were located in the trunk. Tumor size correlated with peak FGF23 (R = 0.566, P < .001) but was not associated with malignancy risk (P = .479). A cut-off FGF23 of >20 times upper limit of normal in the presence of normal renal function (P = .025) and recurrence after initial cure (P = .013) were factors significantly associated with malignancy. The nonlocalizing group had lower survival than the localizing group (P = .0097). Conclusion: TIO is a condition with significant morbidity. Very high FGF23 levels and disease recurrence are associated with malignant disease. Reasons behind the observation of higher mortality in nonlocalizing TIO should be further explored.
- 20 March 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (2) , e397-e411
A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease
Context: Tumor-induced osteomalacia (TIO) is a rare condition with evidence mostly derived from case reports and case series. Objective: We aimed to describe the clinical characteristics of a large cohort of patients diagnosed with TIO, with a focus on patients with nonlocalizing and malignant TIO. Methods: This is a retrospective cohort of patients with TIO in an academic medical center, diagnosed between January 1998 and May 2023. We describe their demographics, biochemistries, tumor features, localization, treatment, and complications. Results: Of 68 patients diagnosed with TIO, 49 (72%) were localizing and 5 (7.4%) were malignant. Of 50 patients who attempted localizing procedures, 29 (58%) achieved cure. Twenty (40%) had persistent disease due to the wrong tumor targeted, or refractory or recurrent tumors, despite up to 6 procedural attempts. There was no difference in demographics, phosphorus, or baseline fibroblast growth factor-23 (FGF23) levels between localizing vs nonlocalizing groups, and malignant vs nonmalignant groups. The lower extremity was the commonest site of localization (37%), with 47% in bone and 53% in soft tissue. Sixty percent of malignant cases were located in the trunk. Tumor size correlated with peak FGF23 (R = 0.566, P < .001) but was not associated with malignancy risk (P = .479). A cut-off FGF23 of >20 times upper limit of normal in the presence of normal renal function (P = .025) and recurrence after initial cure (P = .013) were factors significantly associated with malignancy. The nonlocalizing group had lower survival than the localizing group (P = .0097). Conclusion: TIO is a condition with significant morbidity. Very high FGF23 levels and disease recurrence are associated with malignant disease. Reasons behind the observation of higher mortality in nonlocalizing TIO should be further explored.
- 30 September 2022
- Published by Springer Nature
- p. 849-866
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Non-circulatory Methods of Measurement
- 30 September 2022
- Published by Springer Nature
- p. 849-866
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Non-circulatory Methods of Measurement
- 30 September 2022
- Published by Springer Nature
- p. 867-888
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers
- 30 September 2022
- Published by Springer Nature
- p. 867-888
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers
- 9 June 2022
- Published by Springer Nature
- p. 1-22
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers
- 9 June 2022
- Published by Springer Nature
- p. 1-22
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers
- 20 May 2022
- Published by Springer Nature
- p. 1-18
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Non-circulatory Methods of Measurement
- 20 May 2022
- Published by Springer Nature
- p. 1-18
Measures of Endothelial Function in Type 2 Diabetes: A Focus on Non-circulatory Methods of Measurement
- 4 August 2021
- Published by Springer Nature in Acta Diabetologica
- Vol. 58 (12) , 1701-1704
High glycaemic variability is associated with progression of COVID-19
- 4 August 2021
- Published by Springer Nature in Acta Diabetologica
- Vol. 58 (12) , 1701-1704
High glycaemic variability is associated with progression of COVID-19